PTH and chronic kidney disease: However, this treatment is indicated for patients with CKD who start renal replacement therapy such as dialysis or patients with primary hyperparathyroidism (HPT), and the use of calcimimetics in the predialysis stage is questioned since reducing PTH levels causes a reduction in its phosphaturic effect and thus increases serum phosphorus levels, making it difficult to control hyperphosphatemia in these stages [32].